Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afimoxifene - BHR Pharma

Drug Profile

Afimoxifene - BHR Pharma

Alternative Names: 4-Hydroxytamoxifen; 4-Hydroxytamoxifen (afimoxifene) gel; 4-Hydroxytamoxifen gel; 4-OH tamoxifen; 4-OHT; TamoGel

Latest Information Update: 08 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Besins International
  • Developer Besins Healthcare; BHR Pharma
  • Class Antineoplastics; Hydroxytestosterones; Non-opioid analgesics
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • No development reported Breast pain; Gynaecomastia; Hyperplasia
  • Discontinued Keloids

Most Recent Events

  • 08 Mar 2022 No development reported - Phase-III for Hyperplasia in Spain, Germany, USA (Topical)
  • 03 Feb 2020 Afimoxifene is still in phase III trials for Hyperplasia in USA, Germany and Spain (NCT03199963)
  • 04 Jul 2019 Northwestern University and National Cancer Institute plan a phase II trial in Breast cancer (NCT04009044; NCI-2019-03771; NU 18B05)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top